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Background: Incident atrial fibrillation (AF) is reported in 10%–65% of patients without previous 
AF diagnosis after open heart surgery. The risk of late AF recurrence after a postoperative AF 
onset is unclear, and it is controversial whether AF limited to the postoperative period should 
elicit oral anticoagulation (OAC) therapy. The primary objective of this study was to evaluate 
the long-term recurrence of AF in patients developing new-onset peri-procedural AF.
Patients and methods: Patients (n=189) with available baseline and follow-up data included 
in Left Atrial Appendage Closure with Surgery trial were coded for known AF at baseline 
and for postoperative first-time AF diagnosis. AF occurrence was classified as follows: peri-
procedural #7 days postoperatively, early .7 days but #3 months and late .3 months. 
Patients with no AF recurrence registered during follow-up were invited to undergo Holter 
monitoring.
Results: A total of 163 (86.2%) patients had no history of AF. Among these, 80 (49.1%) devel-
oped new-onset peri-procedural AF. After a mean follow-up of 3.7±1.6 years, late AF occurred 
in 35 of the 80 (43.8%) patients who developed peri-procedural AF and in 6 additional patients 
(7.2%) who remained in sinus rhythm until discharge (hazard ratio [HR] 9.3, 95% CI 3.8–22.4, 
p,0.001). Patients with peri-procedural AF and early AF had 12.24 times higher risk of late AF 
(95% CI 4.76–31.45, p,0.001) as compared to the group with no postoperative AF.
Conclusion: New-onset of AF after open heart surgery has a high rate of recurrence and should 
not be regarded as a self-limiting phenomenon secondary to surgery.
Keywords: atrial fibrillation, postoperative atrial fibrillation, heart surgery
Introduction
Oral anticoagulation (OAC) is well established to prevent cardiac thromboembolism in 
patients with atrial fibrillation (AF) not secondary to reversible conditions according to 
their risk profile.1 AF is very common following open heart surgery with a prevalence 
of 10%–65%, highest after a combination of coronary artery bypass grafting (CABG) 
and valve surgery,2 and is associated with prolonged hospital stay, hemodynamic 
instability, an increased risk of stroke and mortality.2–5
However, it is uncertain whether patients with AF detected in the postoperative 
setting should be treated with OAC. The American Association for Thoracic Surgery 
(AATS) acknowledges in the 2014 guidelines for the prevention and management of 
postoperative AF and flutters for thoracic surgical procedures that the ideal duration of 
anticoagulation after postoperative AF is unknown.6 The newest guidelines from the 
European Society of Cardiology (ESC) 2016 state that “good quality data are needed 
to determine whether long-term anticoagulation can prevent strokes in patients with 
post-operative AF at high stroke risk.”7 The newest guidelines from the American Heart 
Association 2014 state that “it is reasonable to administer antithrombotic medication 
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in patients who develop postoperative AF, as advised for 
non-surgical patients” (level of evidence: B).8
We hypothesized that postoperative new-onset AF recurs 
after new-onset postoperative AF and therefore represented 
the onset of AF rather than a transient phenomenon.
Patients and methods
Study design
The study cohort consisted of all patients included in the 
Left Atrial Appendage Closure with Surgery (LAACS) 
study without prior AF diagnosis. In brief, LAACS study 
was a prospective, open-label study on patients scheduled 
for open heart surgery. In LAACS, we randomized patients 
to surgical closure of left atrial appendage closure in addition 
to the planned surgery procedure or control (LAACS study, 
ClinicalTrials.gov unique identifier ID NCT02378116). 
The study was conducted according to the Declaration of 
Helsinki. Patients were included after providing written 
informed consent according to the protocol approved by the 
Ethics Committee of the Capital Region, Denmark (registra-
tion number H-3-2010-017). The protocol included planned 
open heart surgery (coronary artery bypass, valve surgery and 
combination of both and surgery of the aorta) not related to 
endocarditis.
At the time of inclusion, we registered prior AF, other 
medical history and medication, including OAC. All patients 
included in the LAACS trial were followed through their 
electronic hospital medical records for at least 1 year after 
surgery, until the end of the study. This study was based 
on the total cohort of patients without known AF, who 
underwent open heart surgery and who were included in the 
LAACS trial.
perioperative aF (poaF) detection and 
management
All patients were routinely monitored with telemetry for the 
first 3 days after surgery and longer if there had been cases 
of arrhythmia. We classified the occurrence of AF within the 
first 7 days following surgery as POAF. Patients were man-
aged with rhythm or rate control and OAC at the discretion 
of the treating physician. The occurrence of AF in 3 months 
following surgery was considered “early recurrence.”
End point definitions
The primary end point was AF recurrence beyond the first 
3 months after the surgery (late recurrence) among patients 
with POAF. If there were no episodes of AF in the patient’s 
clinical records, they received continuous heart rhythm 
monitoring (Holter) for at least 7 days with any device avail-
able at the outpatient clinic.
All-cause mortality was recorded as the secondary end 
point.
Statistical analyses
All analyses were performed using SAS statistical software 
package version 9.4 (SAS Institute Inc., Cary, NC, USA). 
Continuous variables are presented as mean ± SD and cat-
egorical as number and percentages. After inspection for nor-
mality, differences between the LAACS and control groups 
were evaluated by Student’s t-test (continuous variables) 
and by Chi-square and Fisher’s exact tests for categorical 
variables where appropriate. Logistic and Cox regressions 
were used to estimate risk ratios for peri-procedural and 
late AF/mortality, respectively. Multivariable models were 
developed by including predictor variables with a priori 
presumed influence on the risk of AF occurrence. Due to 
the randomized design, LAACS was a forced covariate in 
all multivariable models. The probability of late AF over 
time among patients with and without POAF was evaluated 
by Fine and Gray9 competing risk regression using death as 
a competing event. For all hypothesis testing, a two-tailed 
p-value ,0.05 was required for statistical significance.
Results
Of the 189 patients included in the main LAACS study, 
163 patients had no history of AF and were included in this 
subanalysis. The mean follow-up was 3.7±1.6 years.
A total of 36 patients were monitored by the study group, 
and the recurrence of AF was found in 21 patients. The 
numbers were added to the findings of AF in clinical setting, 
and the cumulative findings of AF recurrence are mentioned 
in the “Results” section.
poaF
A total of 80 patients (49%) had new-onset POAF, while 
83 (51%) did not have AF. Table 1 depicts the baseline 
characteristics according to POAF.
In multivariable analyses, older age (p=0.03), calcium blocker 
(p=0.01) and surgery type compared to CABG alone (p=0.04) 
remained associated with increased risk of POAF. LAACS was 
significantly associated with a lower risk of postoperative 
AF (odds ratio [OR] 0.40, 95% CI 0.19–0.82, p=0.01; Table 2).
early and late aF after surgery
During the first 3 months following surgery, 43 of the 
80 patients with POAF (54%) had early recurrence of AF, 
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while it occurred in three out of 83 (4%) of those without 
POAF (Figure 1).
Importantly, of the 80 patients with POAF, 35 (43.8%) 
had late recurrence of AF as compared to six (7.2%) patients 
with no postoperative AF. Mortality was not significantly 
different (nine out of 80 patients with POAF and five out 
of 83 without AF, p=0.15). Univariate survival analyses 
demonstrated that patients with POAF had 9.3 times higher 
risk of late AF (p#0.001; Table 3).
As depicted in Table 4, adjusted analyses showed that 
POAF (p,0.001), renin–angiotensin system (RAS) block-
ers (p=0.01), valve surgery alone or combined with CABG 
compared to CABG alone (p=0.01) was associated with late 
recurrence of AF. In addition, POAF followed by early AF 
had a 12-fold higher risk of late AF (hazard ratio [HR] 12.24, 
95% CI 4.76–31.45, p,0.001; Table 4).
Figures 2 and 3 show the cumulative probability of late 
AF according to POAF and early AF, respectively. Patients 
with both POAF and early recurrence had highest probability 
of late recurrence (Table S1).
Discussion
The main finding in our study is that POAF after open heart 
surgery, in patients without previous history of AF, recurs 
in 44% of the cases. This argues that peri-procedural AF 
is a marker of AF well beyond the stress of the surgery. 
Overall, this supports the need to consider a more aggressive 
approach both regarding follow-up of these patients and in 
the prescription of OAC. Thus, this study may contribute 
to filling the gaps in the current guidelines on management 
of POAF.7,8 Our findings also contribute to the discussion 
of transient use of OAC, especially, since patients with 
Table 1 Baseline and postoperative characteristics in relation 
to peri-procedural (#7 days) new-onset aF among patients 
undergoing cardiac surgery in the laaCS study
Variable No AF 
(n=83)
New-onset 
AF (n=80)
p-value
age, years 65.3±10.1 70.5±7.7 ,0.001
Male 71 (85.5) 66 (82.5) 0.60
Clinical characteristics
Congestive heart failure 13 (15.7) 15 (18.8) 0.65
Diabetes 22 (26.5) 21 (26.3) 0.96
Hypertension 60 (72.3) 63 (78.8) 0.32
CHa2DS2-VaSc, unit 2.7±1.5 3.3±1.4 0.01
prior stroke 9 (10.8) 14 (17.5) 0.27
Chronic kidney diseasea 9 (10.8) 17 (21.3) 0.13
Medicine
aSa 68 (81.9) 67 (83.8) 0.86
Clopidogrel 16 (19.3) 12 (15.0) 0.55
Beta blocker 48 (57.8) 49 (61.3) 0.75
Verapamil 2 (2.4) 2 (2.5) 1.00
Calcium blocker 18 (21.7) 32 (40.0) 0.01
RAS blocker 46 (55.4) 37 (46.3) 0.27
Discharged with oaC 20 (24.1) 31 (38.8) 0.04
Statin 70 (84.3) 67 (83.8) 0.97
Procedural characteristics
left atrial appendage 
closure (randomized)
51 (61.4) 32 (40.0) 0.02
Surgery type
aVR only 11 (13.3) 15 (18.8) 0.34
aVR with CaBG 13 (16.3) 21 (26.3) 0.09
aVR with aortic surgery 1 (1.2) 1 (1.3) 1.00
aVR with MVR 1 (1.2) 1 (1.3) 1.00
aortic surgery only 1 (1.2) 0 (0) 1.00
CaBG only 52 (62.7) 34 (42.5) 0.01
CaBG with MVR 2 (2.4) 1 (1.3) 0.58
MVR only 2 (2.4) 7 (8.8) 0.13
Tricuspid surgery only 0 (0) 0 (0) 1.00
Notes: aeGFR,30 mL/min. Data presented as n (%) or mean ± SD.
Abbreviations: AF, atrial fibrillation; ASA, acetyl salicylic acid; AVR, aortic valve 
replacement; CABG, coronary artery bypass grafting; CHA2DS2-VaSc, congestive 
heart failure, hypertension, age ($75 years), diabetes, stroke – peripheral vascular 
disease, age ($65 years), sex category; eGFR, estimated glomerular filtration rate; 
laaCS, left atrial appendage Closure with Surgery; MVR, mitral valve repair or 
replacement; oaC, oral anticoagulation; RaS, renin–angiotensin system.
Table 2 Univariate and multivariate predictors of POAF: within the first 7 days following cardiac surgery in the LAACS studya
Variable Univariate Multivariate
χ2 OR p-value χ2 OR p-value
age 11.9 1.07 (95% CI 1.03–1.11) ,0.001 3.9 1.05 (95% CI 1.00–1.09) 0.03
Male gender 0.3 0.80 (95% CI 0.34–1.85) 0.60 – – –
CHa2DS2-VaSc 6.4 1.33 (95% CI 1.07–1.67) 0.01 – – –
Beta blocker 0.1 1.11 (95% CI 0.59–2.10) 0.75 – – –
Calcium blocker 6.5 2.48 (95% CI 1.23–5.00) 0.01 6.0 2.69 (95% CI 1.22–5.92) 0.01
RAS blocker 1.2 0.70 (95% CI 0.38–1.31) 0.27 – – –
Statin 0.0 0.99 (95% CI 0.43–2.28) 0.97 – – –
laaCS (randomized) 5.7 0.46 (95% CI 0.24–0.87) 0.02 6.3 0.40 (95% CI 0.19–0.82) 0.01
Surgery typeb 7.0 2.37 (95% CI 1.25–4.47) 0.01 4.2 2.11 (95% CI 1.04–4.30) 0.04
Notes: aORs for postoperative (within the first 7 days following cardiac surgery) new-onset AF (yes/no). Multivariate ORs reflect the predictors that remained significant 
at a 95% significance level when including all predictors with a univariate p,0.70 (to remove irrelevant parameters) in stepwise selection. b“Valve” (aortic [n=26] or mitral 
valve replacement [n=8]) or “vessel and valve surgery” (aortic valve replacement with CaBG [n=32], aortic valve replacement with aortic repair [n=2], aortic and mitral valve 
replacement [n=2] or mitral valve replacement with CaBG [n=3]) as compared to “vessel only” (aortic repair [n=1] or CaBG [n=86]).
Abbreviations: AF, atrial fibrillation; CABG, coronary artery bypass grafting; CHA2DS2-VaSc, congestive heart failure, hypertension, age ($75 years), diabetes, stroke – 
peripheral vascular disease, age ($65 years), sex category; laaCS, left atrial appendage Closure with Surgery; oR, odds ratio; poaF, perioperative aF; RaS, renin–
angiotensin system.
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POAF and early recurrence have a high risk of late recur-
rence of AF.
Our results are in line with other studies which also sug-
gest a high rate of recurrence of AF.3,10 According to Ahlsson 
et al3 in their cohort of 571 CABG-operated patients with 
no history of AF, postoperative AF occurred in 28.9%, of 
whom 25.4% had AF at follow-up after a median follow-up 
of 6.9 years. This is further supported by recent data from 
the Framingham Heart Study, where almost two-thirds of 
the patients are initially considered to have AF secondary 
to cardiac surgery recurred within 15 years.10
In our study, we found no significant difference in 
mortality which may be due to the limited number of patients 
in the cohort. Indeed, El-Chami et al11 have analyzed the 
effect of new-onset AF in patients undergoing CABG and 
identified that postoperative onset AF predicted long-term 
mortality with a 21% relative increase in mortality. Impor-
tantly, use of warfarin was associated with improved survival 
in postoperative onset AF patients.11 This could again suggest 
a degree of recurrence.
In our study, we found a high risk of POAF associated 
with advanced age, which is consistent with findings from 
other studies.12,13 We also found that the need for the treat-
ment with RAS blockers was associated with late recurrence 
of POAF, consistent with hypertension and heart failure as 
the known risk factors for AF.2
Interestingly, we found LAACS to significantly reduce 
the risk of postoperative AF, although this was not the aim 
of the study. However, it has been claimed that ligation of 
the left atrium appendage could maintain sinus rhythm in 
patients with AF through electrical remodeling.14
Study limitations
A limitation to this study was that AF diagnosis is mainly based 
on clinical outcomes recorded during clinical setting rather than 
a continuous ECG monitoring in all patients. In addition, the 
study focuses on the recurrence of AF, and not on its substrate, 
which is important to assess the tendency to AF.15
The relatively low absolute event rate in mortality could 
have led to underpowered analysis, notwithstanding this 
would not have altered the main findings of this study.
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Figure 1 Breakdown of all aF events in the main laaCS cohort.
Note: Occurrence of perioperative AF, and occurrence of late AF are marked in bold.
Abbreviations: AF, atrial fibrillation; LAACS, Left Atrial Appendage Closure with Surgery.
Table 3 proportion of patients meeting end points according 
to peri-procedural new-onset aF: during a mean follow-up of 
3.7 years in the laaCS study
End 
point
No AF 
(n=83)
New-onset 
AF (n=80)
HR p-value
late aF 6 (7.2%) 35 (43.8%) 9.3 (95% CI 3.8–22.4) ,0.001
all-cause 
mortality
5 (6.0%) 9 (11.3%) 2.3 (95% CI 0.7–6.9) 0.15
AF/deatha 11 (13.3%) 41 (51.3%) 6.0 (95% CI 3.0–12.0) ,0.001
Note: aComposite end point of first of late AF or death.
Abbreviations: AF, atrial fibrillation; HR, hazard ratio; LAACS, Left Atrial 
appendage Closure with Surgery.
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The management of AF was not homogeneous which 
could have influenced the outcomes of recurrence of AF, 
and finally, there is a possible selection bias in the capacity 
of monitoring the weakest patients opting out of physical 
follow-up.
Conclusion
Our results show that POAF is likely to recur beyond the 
first 3 months after the surgery. Thus, challenging the concept 
that POAF is a transient phenomenon secondary to surgery.
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Figure 2 Cumulative probability of late AF (after 90 days) according to peri-
procedural new-onset aF.
Abbreviation: AF, atrial fibrillation.
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Figure 3 Cumulative probability of late AF (after 90 days) according to peri-
procedural new-onset aF with or without early aF recurrence (within 90 days).
Abbreviation: AF, atrial fibrillation.
Table 4 Univariate and multivariable predictors of late AF (after 90 days) following cardiac surgery: during a mean follow-up of 
3.7 years in the laaCS studya
Variable Univariate Multivariable
χ2 HR p-value χ2 HR p-value
age 2.5 1.03 (95% CI 0.99–1.06) 0.11 – – –
Male gender 0.2 0.82 (95% CI 0.38–1.78) 0.62 – – –
CHa2DS2-VaSc 2.8 1.21 (95% CI 0.97–1.51) 0.09 – – –
Beta blocker 0.4 1.22 (95% CI 0.64–2.31) 0.55 – – –
Calcium blocker 1.1 1.40 (95% CI 0.74–2.66) 0.30 – – –
RAS blocker 2.1 1.60 (95% CI 0.85–3.01) 0.15 6.8 2.48 (95% CI 1.25–4.90) 0.01
Statin 0.8 0.71 (95% CI 0.33–1.54) 0.39 – – –
laaCS (randomized) 0.3 0.85 (95% CI 0.45–1.61) 0.62 – – –
Surgery typeb 7.2 2.42 (95% CI 1.27–4.60) 0.01 6.0 2.36 (95% CI 1.19–4.67) 0.01
new-onset aF (n=80)c 26.4 9.27 (95% CI 3.84–22.39) ,0.001 22.4 8.86 (95% CI 3.59–21.89) ,0.001
no aF (n=83)d na Reference na na Reference na
only peri-procedural aF (n=37)d 13.0 6.88 (95% CI 2.41–19.67) ,0.001 11.7 5.90 (95% CI 2.13–16.37) 0.01
peri-procedural and early aF (n=43)d 29.7 15.78 (95% CI 5.85–42.56) ,0.001 27.0 12.24 (95% CI 4.76–31.45) ,0.001
Notes: aHRs for late (90 days after cardiac surgery) AF (yes/no). Multivariable HRs reflect the predictors that remained significant at a 95% significance level when including 
all predictors with a univariate p,0.70 (to remove irrelevant parameters) in stepwise selection. b“Valve” (aortic [n=26] or mitral valve replacement [n=8]) or “vessel and 
valve surgery” (aortic valve replacement with CaBG [n=32], aortic valve replacement with aortic repair [n=2], aortic and mitral valve replacement [n=2] or mitral valve 
replacement with CaBG [n=3]) as compared to “vessel only” (aortic repair [n=1] or CaBG [n=86]). cPeri-procedural new-onset AF within the first 7 days after surgery 
(yes/no). dNo AF, no peri-procedural or early AF; only peri-procedural AF, peri-procedural AF but no AF occurrence within 90 days; peri-procedural and early AF, peri-
procedural and recurrence of AF within 90 days. Three patients died within the first 90 days and were censored for late AF at the time of death according to peri-procedural 
new-onset aF.
Abbreviations: AF, atrial fibrillation; CABG, coronary artery bypass grafting; CHA2DS2-VaSc, congestive heart failure, hypertension, age ($75 years), diabetes, stroke – 
peripheral vascular disease, age ($65 years), sex category; HR, hazard ratio; NA, not applicable; LAACS, Left Atrial Appendage Closure with Surgery; RAS, renin–angiotensin 
system.
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Clinical implications
A typical everyday scenario of dealing with postoperative 
AF is the attempt to restore sinus rhythm in patients within 
24–48 hours after onset with the use of antiarrhythmic drugs 
or by electrical cardioversion. Patients who are discharged in 
AF are maintained on anticoagulant therapy and referred for 
cardioversion in 4–6 weeks. Patients discharged on antiar-
rhythmic drugs are followed up in the cardiology clinic after 
3 months. In the absence of evident AF, their antiarrhythmic 
drugs are usually stopped. The decision to stop anticoagulant 
therapy is in these cases left to the cardiologist’s discretion.11 
With our data in mind, we believe that patients with POAF, 
and especially those with early recurrence, should be treated 
as other patients with AF, according to the current guidelines 
for the management of AF. This includes use of OAC medi-
cines dependent on their risk factors for thromboembolism.
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Supplementary material
Table S1 Univariate and multivariable predictors of late AF (after 90 days) or death following cardiac surgery: during a mean follow-up 
of 3.7 years in the laaCS studya
Variable Univariate Multivariable
χ2 HR p-value χ2 HR p-value
age 1.8 1.02 (95% CI 0.99–1.05) 0.18 – – –
Male gender 0.2 0.96 (95% CI 0.47–1.96) 0.90 – – –
CHa2DS2-VaSc 1.8 1.14 (95% CI 0.94–1.38) 0.18 – – –
Beta blocker 0.8 1.30 (95% CI 0.73–2.32) 0.37 – – –
Calcium blocker 0.9 1.31 (95% CI 0.74–2.34) 0.85 – – –
RAS blocker 2.7 1.61 (95% CI 0.91–2.85) 0.10 8.2 2.43 (95% CI 1.32–4.47) 0.004
Statin 0.3 0.81 (95% CI 0.39–1.66) 0.56 – – –
laaCS (randomized) 0.3 0.86 (95% CI 0.49–1.51) 0.60 – – –
Surgery typeb 8.0 2.27 (95% CI 1.29–3.98) 0.004 7.3 2.32 (95% CI 1.26–4.27) 0.007
new-onset aFc 26.4 6.03 (95% CI 3.04–11.97) ,0.001 24.9 6.37 (95% CI 3.08–13.20) ,0.001
Notes: aHRs for late (90 days after cardiac surgery) AF (yes/no). Multivariable HRs reflect the predictors that remained significant at a 95% significance level when including 
all predictors with a univariate p,0.70 (to remove irrelevant parameters) in stepwise selection. b“Valve” (aortic [n=26] or mitral valve replacement [n=8]) or “vessel and valve 
surgery” (aortic valve replacement with CaBG [n=32], aortic valve replacement with aortic repair [n=2], aortic and mitral valve replacement [n=2] or mitral valve replacement 
with CaBG [n=3]) as compared to “vessel only” (aortic repair [n=1] or CaBG [n=86]). cPeri-procedural new-onset AF within the first 7 days after surgery (yes/no).
Abbreviations: AF, atrial fibrillation; CABG, coronary artery bypass grafting; CHA2DS2-VaSc, congestive heart failure, hypertension, age ($75 years), diabetes, stroke – 
peripheral vascular disease, age ($65 years), sex category; HR, hazard ratio; NA, not applicable; LAACS, Left Atrial Appendage Closure with Surgery; RAS, renin–angiotensin 
system.
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